Associate Professor of Medicine, University of Arizona College of Medicine
Hematology
Dr. Daniel O. Persky, MD
|
|
Give Review
Daniel Persky works in the field of Hematology. He attended Albert Einstein College of Medicine of Yeshiva University. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Daniel Persky is a published doctor and has 26 publications published. The lastest was: 'Role of Maintenance Therapy following High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review.' He accepts all Medicare patients.
Publications
- Role of Maintenance Therapy following High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review.
- Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high risk limited stage aggressive B-Cell lymphoma: SWOG S0313.
- Phase II study of imexon, a pro-oxidant molecule, in relapsed and refractory B-Cell non-Hodgkin lymphoma.
- Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-Cell non-Hodgkin lymphoma.
- Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-Cell lymphoma.
- Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas.
- Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cel...
- Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-Cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0...
- Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma.
- AT9283, a novel aurora kinase inhibitor suppresses tumor growth in aggressive B-Cell lymphomas.
- High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin Lymphoma.
- Localized large Cell lymphoma: is there any need for radiation therapy?
- Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-Cell lymphoma treated with R-CHOP.
- Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2.
- A rare presentation of in situ mantle Cell lymphoma and follicular lymphoma: a case report and review of the literature.
- Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis).
- A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin Lymphoma: Southwest oncology group study S0108.
- Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-Cell lymphoma.
- Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle Cell lymphoma.
- Prognostic impact of proliferative index determined by quantitative image Analysis and the International Prognostic Index in patients with mantle cell lymphoma.
- Interactions of elongation factor 1alpha with F-actin and beta-actin mRNA: implications for anchoring mRNA in Cell protrusions.
- Infused peripheral blood autoGraft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopo...
- The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem Cell transplantation in...
- Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-Cell lymphoma: Southwest Oncology Gr...
- The role of cytotoxic and regulatory T Cells in relapsed/refractory Hodgkin lymphoma.
Schools
Albert Einstein College of Medicine of Yeshiva University
Mayo Grad School Med
Mayo School Of Graduate Education
Memorial SloanKettering Cancer Center
Meml Sloan Kettering Cancer Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Memorial Sloan-Kettering Cancer Center -
Mayo School of Graduate Medical Education -
Albert Einstein College of Medicine of Yeshiva University
Drug Facts
| NPI NUMBER | 1285736033 | |
| NPPES Provider LastName | PERSKY | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 857240001 | |
| NPPES Provider State | AZ | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 74.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285736033 |
| Last Name Of The Provider | PERSKY |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Raymond Taetle, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daruka Mahadevan, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Andrew M. Yeager, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashad A. Aboul-Nasr, MD |
|
|
Dr. Mehrnoosh Zarkoob, MD |
|
|
Dr. Marilyn K. Croghan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Quentin S. Ringenberg, MD |
|
|
Dr. Evan M. Hersh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hitendra R. Patel, MD |
|
|
Dr. Natalie A. Swansen, MD
This Doctor is OpenDoctor Recommended.
|